MYNDF
Price
$0.01
Change
-$0.05 (-83.33%)
Updated
Jan 31 closing price
Capitalization
1.68M
NERV
Price
$1.82
Change
-$0.02 (-1.09%)
Updated
Feb 21 closing price
Capitalization
12.73M
23 days until earnings call
Ad is loading...

MYNDF vs NERV

Header iconMYNDF vs NERV Comparison
Open Charts MYNDF vs NERVBanner chart's image
MYND Life Sciences
Price$0.01
Change-$0.05 (-83.33%)
Volume$3.33K
Capitalization1.68M
Minerva Neurosciences
Price$1.82
Change-$0.02 (-1.09%)
Volume$27.68K
Capitalization12.73M
MYNDF vs NERV Comparison Chart
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MYNDF vs. NERV commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MYNDF is a Hold and NERV is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (MYNDF: $0.01 vs. NERV: $1.82)
Brand notoriety: MYNDF and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MYNDF: 86% vs. NERV: 50%
Market capitalization -- MYNDF: $1.68M vs. NERV: $12.73M
MYNDF [@Biotechnology] is valued at $1.68M. NERV’s [@Biotechnology] market capitalization is $12.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MYNDF’s FA Score shows that 1 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • MYNDF’s FA Score: 1 green, 4 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, MYNDF is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 2 TA indicator(s) are bullish.

  • NERV’s TA Score: 2 bullish, 7 bearish.

Price Growth

MYNDF (@Biotechnology) experienced а 0.00% price change this week, while NERV (@Biotechnology) price change was -7.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

NERV is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NERV($12.7M) has a higher market cap than MYNDF($1.68M). NERV YTD gains are higher at: -18.077 vs. MYNDF (-78.032). NERV has higher annual earnings (EBITDA): 3.47M vs. MYNDF (-273.7K). NERV has more cash in the bank: 26.5M vs. MYNDF (1.81K). NERV has less debt than MYNDF: NERV (0) vs MYNDF (3M). MYNDF has higher revenues than NERV: MYNDF (1) vs NERV (0).
MYNDFNERVMYNDF / NERV
Capitalization1.68M12.7M13%
EBITDA-273.7K3.47M-8%
Gain YTD-78.032-18.077432%
P/E RatioN/AN/A-
Revenue10-
Total Cash1.81K26.5M0%
Total Debt3M0-
FUNDAMENTALS RATINGS
NERV: Fundamental Ratings
NERV
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NERV
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GPEOX11.95N/A
N/A
Grandeur Peak Emerg Mkts Opps Inv
AFDVX22.10N/A
N/A
Applied Finance Explorer Investor
FFANX13.30N/A
N/A
Fidelity Asset Manager 40%
PRCOX60.83N/A
N/A
T. Rowe Price U.S. Equity Research
IOLZX27.43N/A
N/A
ICON Equity Institutional

MYNDF and

Correlation & Price change

A.I.dvisor tells us that MYNDF and NERV have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MYNDF and NERV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYNDF
1D Price
Change %
MYNDF100%
N/A
NERV - MYNDF
29%
Poorly correlated
-1.09%
ICCC - MYNDF
23%
Poorly correlated
+0.20%
CSBR - MYNDF
20%
Poorly correlated
-3.05%
AEON - MYNDF
7%
Poorly correlated
+12.12%
INKT - MYNDF
4%
Poorly correlated
+2.46%
More